CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine - The ROPA-DOP Trial The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure

JOURNAL: Article Link

经皮冠状动脉介入治疗后的积极降脂治疗--目标人群以及如何开展?

作者:Zhen-Vin Lee等 译者:左广峰 审校:姜潇

摘要

尽管经皮冠状动脉介入治疗 (PCI) 对阻塞性冠状动脉疾病的疗效是确切的,但考虑到非手术相关的其他重要危险因素的控制程度,尚不能确保长期预后。动脉粥样硬化作为血脂异常的结果,其发展导致的风险具有连续性,因此对接受PCI的患者采取二级预防措施,对于降低手术失败以及心血管事件的风险尤为重要。本综述通过总结最新临床指南推荐,强调三种主流降脂疗法相关理论和证据(即他汀类药物、依折麦布和前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型(PCSK9)抑制剂),概述以二级预防为目的降脂治疗现状。同时,揭示了血脂异常二级预防在实践过程中的挑战和问题,如对未达最佳血脂标准及依从性差等问题提出了可行性方案。